The assay aims to screen for inhibitors of the MLL-CXXC domain and HOX-A DNA interaction in order to potentially reverse leukemogenesis caused by chromosomal translocation of the MLL gene. The N-terminal of MLL fusion proteins always consists of the N-terminal menin binding motif and the CXXC domain, which specifically recognizes unmethylated CpG sequences of the HOX-A gene. The disruption of this interaction results in the down regulation of HOX-A gene expression, which is responsible for the development of MLL fusion leukemias. The optimized in-vitro assay may have utility in developing treatments for MLL fusion leukemias. Is the molecule effective to this assay?